|
NEO1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62658775337832E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
4.79094541816494E-12 |
| Normal-vs-Stage2 |
2.12299999999832E-05 |
| Normal-vs-Stage3 |
1.97180050065526E-10 |
| Normal-vs-Stage4 |
4.3115511161318E-12 |
| Stage1-vs-Stage2 |
3.714600E-01 |
| Stage1-vs-Stage3 |
2.007000E-01 |
| Stage1-vs-Stage4 |
6.462900E-03 |
| Stage2-vs-Stage3 |
8.252500E-02 |
| Stage2-vs-Stage4 |
1.110290E-02 |
| Stage3-vs-Stage4 |
1.571780E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.44169137633799E-15 |
| Normal-vs-AfricanAmerican |
2.461800E-03 |
| Normal-vs-Asian |
1.023200000283E-07 |
| Caucasian-vs-AfricanAmerican |
9.584400E-02 |
| Caucasian-vs-Asian |
5.361400E-01 |
| AfricanAmerican-vs-Asian |
2.758800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.86897197507597E-12 |
| Normal-vs-Female |
1.65845115418506E-12 |
| Male-vs-Female |
4.271800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.7719610181457E-12 |
| Normal-vs-Age(41-60Yrs) |
4.98669994186685E-11 |
| Normal-vs-Age(61-80Yrs) |
1.20920051749351E-10 |
| Normal-vs-Age(81-100Yrs) |
5.641800E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.883200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.404800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.846600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.756390E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.347800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.152600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.353400E-04 |
| Classical-VS-Follicular |
8.304100E-02 |
| Classical-VS-Other |
1.785240E-01 |
| Classical-VS-Normal |
3.45809999524604E-08 |
| Tall-VS-Follicular |
9.875700E-02 |
| Tall-VS-Other |
9.721400E-01 |
| Tall-VS-Normal |
2.16060502822302E-11 |
| Follicular-VS-Other |
4.535200E-01 |
| Follicular-VS-Normal |
1.28480004413234E-10 |
| Other-VS-Normal |
9.014100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.04449782156735E-12 |
| Normal-vs-N1 |
1.94170013401163E-10 |
| N0-vs-N1 |
1.653200E-01 |
|
|
